The honest bottom line arrives before the detail: ARA-290, also called cibinetide, has produced a repeatable early signal in sarcoidosis-associated small fiber neuropathy, and nothing more definitive than that. Three short randomized, double-blind, placebo-controlled studies published between 2012 and 2017 enrolled 22, 38 and 64 patients for four weeks each, reporting improvements in neuropathic symptom scores and increases in corneal nerve fiber measures relative to placebo. For a patient weighing options, the distinction that matters is that these are exploratory research signals from a program that never reached confirmatory testing, in a compound no regulator has approved for any indication.
The entire clinical record for ARA-290 in sarcoidosis-associated small fiber neuropathy consists of three early-phase randomized placebo-controlled studies totaling 124 participants dosed for four weeks each, with no confirmatory phase 3 trial reported and no regulatory approval anywhere.
Three peer-reviewed randomized, double-blind, placebo-controlled reports carry the entire sarcoidosis evidence base, and all three are early phase. They escalate in a readable way, from a 22-patient intravenous pilot in 2012, to a 38-patient subcutaneous study in 2013 that added a structural nerve measure, to a 64-patient dose-comparison study in 2017 that promoted that structural measure to the primary endpoint. What the sequence does not represent is independent replication: the same overlapping set of investigators ran all three.
| Criteria | 2012 pilot | 2013 study | 2017 dose comparison |
|---|---|---|---|
| Randomized participants | 22 | 38 | 64 |
| Route | Intravenous infusion, 3x weekly | Daily subcutaneous | Daily subcutaneous |
| Treatment window | 4 weeks | 28 days | 28 days |
| Central endpoint | Small Fiber Neuropathy Screening List | Symptom scales plus corneal nerve fiber density | Corneal nerve fiber area |
Three randomized double-blind placebo-controlled reports published in 2012, 2013 and 2017 enrolled 22, 38 and 64 sarcoidosis patients respectively, and no completed confirmatory phase 3 trial in this indication appears in the published literature.
Every published sarcoidosis protocol delivered ARA-290 by injection, because the peptide is not orally bioavailable and its measured circulating half-life in humans runs on the order of minutes. That short half-life shaped the design question the trials were built to answer: whether brief receptor engagement could set off a longer-lasting tissue response, rather than whether sustained blood levels could be maintained. These regimens are documented facts about supervised research protocols under eligibility screening and clinician monitoring, and no regulator has evaluated any of them for safety or effectiveness outside that setting.
Published sarcoidosis protocols used injected doses of 1 to 8 mg per administration over treatment windows of four weeks or 28 days, with no regimen evaluated by any regulator for use outside a supervised trial.
Small fiber neuropathy is defined largely by what patients feel rather than by what standard nerve conduction studies can detect, which pushed these trials onto patient-reported instruments. That reliance is also the weak point in the record. A statistically detectable shift on a symptom scale is not automatically a change a patient would notice, the minimal clinically important difference for several of these instruments is not firmly established in a sarcoidosis population, and neuropathic pain trials are known for large placebo responses when the intervention is an injection given over a brief window.
The sarcoidosis trials reported symptom and pain improvements favoring ARA-290 over placebo within four-week treatment windows, measured mainly on the Small Fiber Neuropathy Screening List, an instrument whose minimal clinically important difference in this population is not firmly established.
Corneal confocal microscopy became the signature measurement of this research program, imaging the subbasal nerve plexus of the cornea without a biopsy and yielding quantitative counts of nerve fiber density, length, branch density and total fiber area. The 2013 and 2017 studies both reported greater corneal nerve abundance in treated arms than in placebo arms over roughly four weeks, the strongest structural claim in the literature and also the place where interpretive debate concentrates. Measurable subbasal nerve change inside four weeks is fast for regeneration, and whether those shifts reflect true regrowth, reduced inflammatory retraction, or measurement drift has not been settled by studies of this size.
The 2013 and 2017 studies both reported increased corneal nerve fiber measures on ARA-290 relative to placebo over roughly four weeks, but no regulator has validated corneal nerve fiber change as a surrogate endpoint that can stand in for clinical benefit in a registration trial.
The rationale traces back to a puzzle about erythropoietin: it appeared to protect injured tissue, yet its red-cell-stimulating activity made chronic use for that purpose unsafe because of thrombotic and hypertensive risk. The proposed resolution was that tissue protection ran through a separate receptor assembly, and that a short peptide could engage it without triggering erythropoiesis. Two caveats belong beside this account, since the innate repair receptor concept has not reached the level of independent structural and pharmacological confirmation that long-established receptor systems carry, and a mechanism built on nerve regeneration sits awkwardly against symptom changes reported inside a few weeks.
ARA-290 is an eleven-amino-acid erythropoietin-derived peptide designed to engage the proposed innate repair receptor without stimulating erythropoiesis, a mechanism supported by rodent models and mechanistic reasoning rather than by confirmed human pathway evidence.
Within the narrow bounds of what was actually studied, the published sarcoidosis trials described ARA-290 as generally well tolerated across four-week exposures, with no sign of the hemoglobin elevation, blood pressure rise, or thrombotic signal that constrain erythropoietin itself. The more important reading is what this record structurally cannot establish. A few dozen participants dosed for a month can surface only common, early, obvious problems, and chronic modulation of an anti-inflammatory and tissue-repair pathway raises questions about immune surveillance and abnormal cell growth that trials of this length are incapable of answering.
Tolerability findings drawn from 124 participants dosed for four weeks can detect only common, early adverse events, and they carry no information about uncommon events, delayed effects, or the consequences of chronic exposure.
The honest summary of this evidence base is that it is suggestive and unfinished. Small cohorts leave wide confidence intervals around every reported effect, where a single unusual responder or dropout can move a group mean, and roughly a month of treatment says nothing about whether any benefit persists, accumulates or fades once dosing stops. Eligibility criteria also selected a narrow slice of the sarcoidosis population, patients with confirmed disease and clinically evident small fiber symptoms, so extension to milder cases, other granulomatous conditions, or neuropathies of different cause remains speculative.
Settling whether ARA-290 benefits sarcoidosis-associated small fiber neuropathy would require an adequately powered, multicenter, longer-duration trial with prespecified clinical endpoints, independent blinded adjudication and post-treatment follow-up, and no such completed trial has been reported.
ARA-290 remains an investigational compound, unapproved by the United States Food and Drug Administration, the European Medicines Agency, or any comparable national regulator for sarcoidosis-associated small fiber neuropathy or any other condition, and unavailable as a prescription medicine. Development-stage designations intended to encourage rare-disease work have been reported in connection with the program, and they are routinely mistaken for approval; they are procedural incentives granted early, not findings that a compound works or is safe. Material sold under this name through research chemical or gray-market channels sits entirely outside the regulatory system, with no verified identity, purity, sterility or content, and its availability for purchase says nothing about clinical evidence.
ARA-290 holds no marketing approval from the FDA, the EMA, or any comparable regulator for any indication, and rare-disease development designations reported for the program are procedural incentives rather than findings of safety or effectiveness.
The sarcoidosis work did not stand alone. A parallel line of early-phase, randomized, placebo-controlled research examined ARA-290 in people with type 2 diabetes and small fiber neuropathy, using a broadly similar endpoint toolkit and reporting directionally similar results. That apparent consistency cuts both ways, because the two conditions damage small fibers by very different routes, so a shared benefit would imply the peptide acts on a final common pathway of nerve injury and repair, a strong and largely untested claim. Working against that reading, the two programs shared investigators, sponsor involvement, endpoint choices and measurement techniques, which makes their agreement weaker evidence than agreement between genuinely independent programs.
| Criteria | Sarcoidosis program | Diabetic neuropathy program |
|---|---|---|
| Injury route | Immune-mediated granulomatous inflammation | Chronic metabolic and microvascular damage |
| Endpoint toolkit | Corneal nerve metrics, sensory testing, symptom scales | Same toolkit plus glycemic and lipid measures |
| Reported direction | Symptom and corneal nerve gains over placebo | Similar gains, clearest below 1 SD baseline corneal density |
| Independence | Shared investigators and sponsor involvement | Same investigator network and sponsor |
| Confirmatory stage | Not reached | Not reached |
ARA-290 produced a repeatable early signal on the same symptom and corneal nerve measures across both sarcoidosis and diabetic small fiber neuropathy populations, but the shared investigators, sponsor and endpoint choices across those programs make the agreement weaker evidence than independent replication would provide.
Educational use only. This article describes what the published scientific and clinical literature reports about ARA-290. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
